PDS Biotechnology Corporation — Q1 2022 Form 10-Q
Period: Three months ended March 31, 2022. PDS is a clinical-stage immunotherapy company developing oncology and infectious-disease candidates using its Versamune and Infectimune platforms. It has no commercially approved products and reported no product revenue.
Financial performance and position
| Metric | Q1 2022 | Q1 2021 / prior period |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $5.16 million | $1.41 million |
| General and administrative expense | $3.32 million | $1.64 million |
| Total operating expenses | $8.48 million | $3.05 million |
| Net loss | $8.47 million | $3.05 million |
| Net loss per share, basic and diluted | $0.32 | $0.14 |
| Cash used in operating activities | $6.37 million | $3.80 million |
| Cash and cash equivalents at quarter-end | $58.88 million | $65.24 million at Dec. 31, 2021 |
Operating expenses rose 178% year over year. R&D increased primarily due to manufacturing and quality costs, clinical study and regulatory costs, and personnel. G&A growth primarily reflected higher personnel and legal costs. No operating margin is meaningful given the absence of revenue. The filing reports no borrowings; liabilities were $5.17 million, including operating lease obligations. Stockholders’ equity was $55.87 million.
Material developments, outlook and risks
- Management believes available cash is sufficient to fund operations and R&D for at least one year after the filing date. The company expects continuing losses and higher R&D spending as programs advance; future funding may require equity or debt financing, partnerships, or other sources. No specific earnings or revenue guidance was provided.
- The Phase 2 VERSATILE-002 trial of PDS0101 plus pembrolizumab met a preliminary efficacy milestone in the checkpoint-inhibitor-naive cohort, allowing full enrollment; the company reported the combination was well tolerated in the initial patients. The checkpoint-inhibitor-refractory cohort continued enrolling. These are preliminary results, not final trial outcomes.
- The NCI-led PDS0101 triple-combination trial continued enrollment. PDS0103 was in late preclinical development; after a first-quarter FDA pre-IND meeting, the company planned to submit an IND package in Q4 2022.
- PDS shifted near-term infectious-disease focus toward universal influenza vaccines. The Farmacore COVID-19 vaccine license was due to expire May 31, 2022 after program delays; the stated Brazilian funding commitment of up to approximately $60 million had not been confirmed as available, and clinical development had not begun.
- COVID-19 had delayed or slowed clinical-trial operations and enrollment. Other cited risks include clinical and regulatory uncertainty, dependence on additional capital, competition, intellectual-property protection, and potential supply-chain and cost effects from geopolitical tensions and market volatility.
- A former CFO’s arbitration demand alleges wrongful termination and claims damages of at least $3 million plus other amounts; the company disputes the allegations and is defending the matter. Management did not believe pending matters would materially adversely affect financial position, results, or cash flows. A separate stockholder suit was voluntarily dismissed in February 2022 after stockholder ratification of the equity plan and options.
- After quarter-end, PDS received approximately $1.2 million from the sale of New Jersey tax benefits. The filing also reports that disclosure controls were effective and no material changes to internal control over financial reporting occurred during the quarter.
Key facts for investors to verify
- Cash runway assumptions and the timing and terms of any future financing, including potential dilution or debt constraints.
- Enrollment, efficacy, safety, and milestone progress in PDS0101 trials; distinguish preliminary data from mature results.
- Whether the planned Q4 2022 PDS0103 IND submission occurred and how the influenza program advances.
- The outcome of the former CFO arbitration and the status of the Farmacore license and Brazilian funding.
- Clinical-trial delays, manufacturing costs, and cash burn relative to management’s projections.